CVS Health Beats Q2 Estimates, Raises 2026 Outlook Amid Cautious Outlook

CVS Health posted adjusted earnings of $2.58 per share for the second quarter, well above the Wall Street estimate of $1.85. Revenue reached $106.1 billion, surpassing the $100.1 billion consensus. Net income climbed to $2.98 billion (or $2.31 per share), nearly triple the $1.02 billion recorded a year earlier.

CNBC

The company lifted its full-year 2026 adjusted earnings guidance to $7.90–$8.10 per share, up from the prior $7.30–$7.50 range, and raised its revenue outlook to at least $414 billion, up from $405 billion. For 2027, CVS set a minimum earnings target of $8.44 per share.

CVS Health beats Q2 earnings and revenue estima...

The results reflect progress in CVS’s multi-year turnaround plan, which has emphasized $2 billion in cost reductions, closure of underperforming stores, leadership reshuffles, and tighter Medicare Advantage expense management. Aetna, the insurer subsidiary, showed improved medical loss ratios, helping to offset broader industry pressure from high medical costs.

CNBC

• Revenue growth: +7 % year-over-year.

CVS posts Q2 revenue and earnings well ahead of estimates

• Medical loss ratio (Aetna): 87.4 % vs. 89.9 % a year earlier, below analysts’ 90.03 % estimate.

CNBC

• Medical membership: 26 million as of June 30, unchanged since March 31.

CVS posts Q2 revenue and earnings well ahead of estimates

• Drug mix: Pharmacy segment benefited from a more profitable drug mix and brand-price inflation.

CVS posts Q2 revenue and earnings well ahead of estimates

• Weight-loss drug access: MinuteClinics will offer $29 appointments for prescriptions of Wegovy, Foundayo and Zepbound starting early in the fourth quarter.

Reuters

• Brian Newman, CFO: The 2027 earnings bar of at least $8.44 per share “appears reasonable at this juncture,” aligning with current consensus.

Reuters

• Partnership announcement: CVS will make Eli Lilly’s obesity injection Zepbound and the weight-loss pill Foundayo available through the CVS Health app to both insured and cash-pay patients beginning in the fourth quarter.

CNBC

• “The guidance came in lighter than what the buyside was expecting,” — Stephanie Link, chief investment strategist at Hightower Advisors

Reuters

• “At this point in the year, we're trending to a retention rate that's slightly lower than our historical performance,” — Prem Shah, CVS executive

Reuters

Analysts have not yet incorporated the strong second-quarter beat into their 2027 earnings models, creating a gap between the company’s outlook and market expectations. No other substantive discrepancies appear across the sources.

Reuters

• The company will monitor Caremark’s client retention as it moves away from rebate-based contracts.

CVS posts Q2 revenue and earnings well ahead of estimates

• Implementation of the obesity-treatment offering on the CVS Health app is slated for early Q4.

CVS Health beats Q2 earnings and revenue estima...

• Investors will watch how the 2027 earnings guidance holds up against forthcoming analyst revisions.

Reuters